ALNYAlnylam Pharmaceuticals Inc
ALNY
Alnylam Pharmaceuticals Inc4,434
Mkt Cap
$38.32BVolume
1.15M52W High
$495.5552W Low
$284.19PE Ratio
68.19ALNY Fundamentals
Price
$286.98Prev Close
$293.45Open
$294.7850D MA
$312.86Beta
0.84Avg. Volume
1.11MEPS (Annual)
$2.33P/B
35.61Rev/Employee
$1.49M$53,617.41
New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new analyses from the HELIOS-B Phase 3 study of vutrisiran in patients with the cardiomyopathy of...
Business Wire·6d ago
Alnylam to Webcast Presentations at Upcoming Investor Conferences
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las...
Business Wire·10d ago
Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
Bronte Capital Management Pty Ltd. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent filing...
MarketBeat·11d ago
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type...
Business Wire·13d ago
PFA Pension Forsikringsaktieselskab Buys Shares of 35,405 Alnylam Pharmaceuticals, Inc. $ALNY
PFA Pension Forsikringsaktieselskab bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 35,405 shares of the biopharmaceutical company's stock, v...
MarketBeat·13d ago
PKO Investment Management Joint Stock Co Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
PKO Investment Management Joint Stock Co boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 750.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,800 shares of the biopharmaceutical company's stock afte...
MarketBeat·14d ago
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS
Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 53.1% during the fourth quarter, according to its most recent Form...
MarketBeat·14d ago
Royal Bank Of Canada Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
Royal Bank Of Canada lowered their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an "outperform" rating for the company in a research report on Friday...
MarketBeat·16d ago
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
Zacks·16d ago
Wells Fargo & Company Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an "equal weight" rating in a research note on Friday...
MarketBeat·16d ago
<
1
2
...
>